Patents Assigned to Dana-Farber Cancer Institute, Inc.
  • Host targeted inhibitors of dengue virus and other viruses
    Patent number: 9879003
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 30, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Nathanael Gray, Priscilla Yang, Qingsong Liu, Mélissanne de Wispelaere
  • MEK1 mutation conferring resistance to RAF and MEK inhibitors
    Patent number: 9880169
    Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: January 30, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
  • Oncogene associated with human cancers and methods of use thereof
    Patent number: 9874565
    Abstract: The present invention provides methods of treating cancer by inhibiting MECP2 and identifying cancers that will respond to therapy using MECP2 as a biomarker.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: January 23, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Daniel P. Silver, Manish Neupane, David E. Hill
  • METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
    Publication number: 20180009779
    Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
    Type: Application
    Filed: June 23, 2017
    Publication date: January 11, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Dennis Buckley, Georg Winter
  • Hydrophobically tagged janus kinase inhibitors and uses thereof
    Patent number: 9862688
    Abstract: The present invention provides Janus kinase inhibitors, such as compounds of Formula (I) and Formula (II) wherein RY1 and RY2 comprise a tagged hydrophobic moiety RH. The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). The hydrophobic moiety RH may signal to the intracellular protein homeostasis machinery to induce degradation of the targeted kinase. Also provided are pharmaceutical compositions, kits, methods, and uses that involve the compounds for reducing the activity of a kinase and/or treating and/or preventing a condition associated with aberrant activity of a kinase (e.g., a proliferative disease, inflammatory disorder, autoimmune disorder, painful condition, and/or viral infection).
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: January 9, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Li Tan
  • Selective nucleic acid amplification from nucleic acid pools
    Patent number: 9862994
    Abstract: Provided herein are nucleic acids and methods for selectively amplifying in parallel tens of thousands of high quality oligonucleotides without common sequences. The resultant oligonucleotides can be used for a variety of purposes and applications including but not limited to DNA nano structure synthesis.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: January 9, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Thorsten Lars Schmidt, Mark Theilmann, William M. Shih
  • BH3 peptides and method of use thereof
    Patent number: 9856303
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: January 2, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Biomarkers for the early detection of breast cancer
    Patent number: 9857374
    Abstract: The present invention provides reagents and methods for breast cancer detection.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: January 2, 2018
    Assignees: Arizona Board of Regents, A Body Corporate Acting For and On Behalf of Arizona State University, President and Fellows of Harvard College, Dana Farber Cancer Institute, Inc.
    Inventors: Joshua LaBaer, Karen Sue Anderson, Garrick Wallstrom, Sahar Sibani, Niroshan Ramachandran
  • Methods to treat lymphoplasmacytic lymphoma
    Patent number: 9856223
    Abstract: The present invention provides compounds of any one of Formulae (A), (I-11), (II), and (V) (e.g., compounds of Formula (A-1)-(A-18)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplasm in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 2, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Steven P. Treon, Sara Jean Buhrlage, Nathanael S. Gray, Li Tan, Guang Yang
  • MICROFLUIDIC CELL CULTURE OF PATIENT-DERIVED TUMOR CELL SPHEROIDS
    Publication number: 20170369829
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Application
    Filed: January 7, 2016
    Publication date: December 28, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong
  • Rapid Quantitative Detection of Single Nucleotide Polymorphisms or Somatic Variants and Methods to Identify Malignant Neoplasms
    Publication number: 20170369939
    Abstract: Provided are systems, kits, and methods for the quantitative detection of single nucleotide polymorphisms or variants to identify malignant neoplasms. The methods include use of modified oligonucleotide blockers with peptide nucleic acid backbones that hybridize to and block logarithmic amplification of the wild-type alleles of a target, and incorporation of locked nucleic acids into probes that are complementary to a mutant allele of the target sequence to increase specificity. The methods include detection of variants in sequences with high GC content and/or low complexity, such as the TERT promoter, IDH1, BRAF, NRAS, GNAQ, GNA11 and H3F3 A gene variants. The methods include sensitive detection and staging of cancers with low cellularity, and can be used intraoperatively such as for glioma, or to detect cell-free circulating tumor DNA, such as for melanoma.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 28, 2017
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: MATTHEW MEYERSON, GANESH M. SHANKAR, JOSHUA M. FRANCIS, DANIEL P. CAHILL, MIKAEL L. RINNE
  • IN VIVO METHODS FOR IDENTIFYING CANCER-ASSOCIATED IMMUNOTHERAPY TARGETS
    Publication number: 20170360963
    Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 21, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Natalie Collins
  • Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
    Patent number: 9845356
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same. In one aspect, an isolated monoclonal antibody, or antigen-binding fragment thereof, which specifically binds both PD-L1 and PD-L2, is provided. In one embodiment, both PD-L1 and PD-L2 are human PD-L1 and human PD-L2.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: December 19, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • BPI AND ITS CONGENERS AS RADIATION MITIGATORS AND RADIATION PROTECTORS
    Publication number: 20170354712
    Abstract: Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 14, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Eva Guinan, Ofer Levy
  • Compositions and methods for the modulation of DNA damage responses using BAL1 and BBAP
    Patent number: 9840708
    Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: December 12, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Qingsheng Yan
  • SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE
    Publication number: 20170349595
    Abstract: The present invention provides novel heteroaryl compounds of formula (I) having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers.
    Type: Application
    Filed: April 28, 2017
    Publication date: December 7, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute
    Inventors: Nathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
  • PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR
    Publication number: 20170350891
    Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.
    Type: Application
    Filed: May 12, 2017
    Publication date: December 7, 2017
    Applicant: Dana Farber Cancer Institute, Inc.
    Inventors: William G. KAELIN, JR., Mircea Ivan
  • SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER
    Publication number: 20170342036
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Human monoclonal anti-PD-L1 antibodies and methods of use
    Patent number: 9828434
    Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui
  • Chromosome copy number gain as a biomarker of urothelial carcinoma lethality
    Patent number: 9828643
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda